ESTRO 2024 - Abstract Book

S1609

Clinical - Lung

ESTRO 2024

Concomitant Sequential No chemotherapy

155

(88%)

101

(89%)

54

(86%)

17

(10%)

12

(11%)

5

(8%)

5 (3%)

1 (1%)

4 (6%)

Diagnostic MRI-cerebrum

90 (51%)

45 (39%)

45 (71%)

P < 0.01

Treatment

period

Early

2021-2016

85

(48%)

71

(62%)

14

(22%)

P < 0.01

Late 2017-2020

92 (52%)

43 (38%)

49 (78%)

First failure intracranial

27 (15%)

14 (12%)

13 (21%)

P = 0.14

Parameters that significantly (P<0.05) impacted referral for PCI were tested first. Secondly, Kaplan-Meier estimates were compared in the two groups using log-rank test. OS was defined as time from start of radiotherapy treatment till death. Finally, a multivariate Cox Regression analysis on gender, ECOG performance status (PS), stage, treatment period and PCI was performed to determine if any of these impacted OS independently.

Results:

Pts not receiving PCI were older, had a poorer PS, had more likelihood of a diagnostic MRI-cerebrum, and were treated in the later period compared to pts treated with PCI. Median follow-up was 72 months, the median OS (mOS) was 22 months (CI 95% 18.1-25.9) for the entire cohort with a 2-year survival rate of 48% and a 5-year survival rate of 24%. The mOS was 23 months (CI 95% 18.8-27.2) for the pts treated with PCI and 20 months (CI 95% 14.5 25.6) for the pts that were not. There was no significant difference in OS between the two groups in a univariate comparison (P = 0.61) [Fig. 1]. In multivariate analysis of the parameters listed previously, only stage impacted OS [Table 2].

Conclusion:

Physicians were less likely to refer pts for PCI in newer times, if pts were older, had impaired PS or if MRI-cerebrum was available at diagnosis. No significant difference in OS was observed between patients treated with or without